Two of the hottest growth names in the market. One week. Nearly $300M in insider sales. Both stocks fell hard.
Insiders at Rocket Lab (RKLB) and CoreWeave (CRWV) filed back-to-back Form 4s and the crowd took notice. But the Stoxcraft scoring system doesn't treat these two situations the same. One is a glass cannon story. The other is something more concerning.
Here's what the scores actually say.
of investors rely on social media or forums as their main source of stock ideas
Main source of stock ideas
48%
Two insiders, same week, nearly $300M in sales
Rocket Lab CEO Peter Beck's family trust sold 3,275,779 shares over July 6, 7, and 8, 2026. Prices ran from $81.59 to $101.57 per share, totaling $286.4M. Pre-scheduled under a Rule 10b5-1 plan adopted in March 2026. Planned months before the sale. Not a reaction to anything that happened last week.
CoreWeave CSO Brian Venturo followed the same playbook. He sold $12.9M in CoreWeave Class A shares on June 30 and July 1, at prices between $85.05 and $95.69. Also a pre-scheduled 10b5-1 plan. Both men cashed out while their stocks were dropping.
Pre-planned sales carry less signal than discretionary ones. But the score context behind each name is what changes the picture entirely.
Flowed into markets after meme stock rallies
Meme stock rallies
$1.3T
Rocket Lab: elite returns, extreme risk
RKLB is a stat sheet most RPG players would recognize. One attribute maxed out. Another at the floor. That kind of build wins big and dies fast.
Rocket Lab's Performance Score ranks in the top 3% of the universe
RKLB holds a Performance Score of 9.3/10. Top 3% of all 3,500+ stocks tracked on Stoxcraft. Near the 90th percentile cap of the scoring range. The driver is a three-year return of +1,211% and a one-year return of +107.6%. Even with a brutal trailing-month pullback of -29.4%, the multi-year numbers keep the score near the ceiling.
A Performance Score above 8.0 already sits near the 90th percentile. RKLB is above that. Most stocks in the database never get close.
Rocket Lab's Health Score sits in the bottom tier
The flip side is brutal. No cushion. No margin.
RKLB carries a Health Score of 1.5/10. Bottom tier of the database. Negative operating cash flow of -$48.9M and a net loss of -$190M are the main drags. The company runs fast and burns cash doing it. That's not a new problem. RKLB has always been a high-burn, high-growth story. But it matters more right now because of what just landed on the balance sheet.
The Iridium deal raises the stakes for RKLB holders
Rocket Lab struck an $8B deal to acquire satellite communications provider Iridium Communications, betting on a SpaceX-style advantage that combines a live satellite constellation with in-house rockets to launch them. Ambitious. Also expensive. The capital commitments land on top of a balance sheet that's already stretched thin.
Then Neutron. A fuel tank defect during testing pushed the first flight back to Q4 2026. A failure there would severely complicate refinancing the Iridium acquisition.
RKLB's Risk Score sits at 10.0/10, the maximum in the database. Higher means more risk. A beta of 2.55 means the stock moves roughly 2.5x the market in either direction. That's a high-wire act even when the fundamentals are clean. At a Health Score of 1.5/10 with an $8B acquisition in flight, there's no net.
Overall rating: 2.5 stars. The performance history is real. The risk profile is also real. There's almost no margin for error here.
CoreWeave: when the scores already told the story
CRWV is a different problem. RKLB's insider sale runs against its performance track record. CRWV's sale runs with the data. The warning signs were in the scores before Venturo filed anything.
CoreWeave's Health Score reflects a balance sheet under structural pressure
CRWV carries a Health Score of 2.1/10. Bottom 5% of all technology companies tracked on Stoxcraft. The main driver: negative shareholder equity of -$414M sitting against $10.6B in total debt. That's not a company absorbing short-term losses to build something. That's a structurally weak balance sheet carrying one of the highest debt loads relative to equity in the entire tech coverage universe.
Current ratio below 1. Short-term liabilities exceed short-term assets. Thin foundation.
CoreWeave's Performance Score is well below the universe median
CRWV's Performance Score is 3.9/10. Below median for the coverage universe. The three-year return of +122% looks solid until you check what's happened since: one-year return -29.4%, three-month return -12.9%, one-month return -7.2%. Consistently down across every short time horizon.
Compare that to RKLB at 9.3/10. The gap is enormous. CRWV isn't a recovery play right now. It's a high-volatility story with momentum pointed the wrong way.
CoreWeave's Risk Score places it among the most volatile stocks tracked
CRWV's Risk Score of 9.9/10 is nearly identical to RKLB's. The difference: the fundamentals behind it are weaker. A beta of 7.13 makes CRWV one of the most volatile names in the entire Stoxcraft universe. It swings hard in both directions. With negative equity, $10.6B in debt, and drawdown risk near the maximum, a -15% week isn't a surprise. It's the expected range of outcomes for a stock built like this.
Overall rating: 1 star. No offset from performance. Weak health, below-average performance, near-maximum risk. Every dimension pointing the same direction.
What separates RKLB and CRWV despite the same headline signal
Both stocks. Insider sales. Falling prices. Same week. That's where the similarity ends.
RKLB's 2.5-star overall rating sits on top of a genuine performance track record. The risks are extreme, but they've always been extreme. Investors who understood this stock before this week understand it the same way now. The sale was pre-scheduled. The Iridium deal is risky, not stupid. The asset base is building even if profitability is still a long road.
CRWV's 1-star rating is different. It doesn't reflect a volatile stock with strong underlying returns. It reflects weak health, declining performance, and near-maximum risk across every dimension. The Venturo sale didn't create that story. It just arrived in the same news cycle as one that was already there.
Pre-planned sale or not: when every score on the card is flashing red before the filing drops, the filing isn't the problem.
What to watch next for RKLB and CRWV holders
Glass cannon, remember. RKLB has a high ceiling and almost no floor. The Neutron rocket outcome in Q4 2026 is the next real test. A successful first flight changes the refinancing math for Iridium significantly. A failure compounds everything.
For CRWV, the stock is trading near the bottom of its 52-week range of $63.80 to $153.20 while every score dimension points the same direction.
The Stoxcraft Screener lets you filter by Health Score, Performance Score, and Risk Score to see where both stocks rank across the full universe today. If you're watching the AI infrastructure space, Nvidia (NVDA) is worth pulling up for comparison across the same dimensions.
This article is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.
